AURA - NASDAQ
Aura Biosciences, Inc.
$6.88
-0.29%Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
At a Glance
Live SnapshotAura Biosciences, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Aura Biosciences, Inc. Balance Sheet
AURA • NASDAQ
| Aura Biosciences, Inc. Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
ASSETS | |||||||
CURRENT ASSETS | |||||||
59.5M | 31.7M | 41.1M | 121.6M | 149.1M | 17.4M | 32.4M | |
84.7M | 119.4M | 185.1M | 67.2M | 0.0 | 0.0 | 0.0 | |
144.2M | 151.1M | 226.2M | 188.8M | 149.1M | 17.4M | 32.4M | |
0.0 | 7.7M | 1.8M | 2.2M | 4.6M | 1M | 45K | |
5.5M | 1.8M | 3.8M | 5.7M | 89K | 35K | 852K | |
149.7M | 160.6M | 231.8M | 196.7M | 153.7M | 18.5M | 33.3M | |
NON-CURRENT ASSETS | |||||||
18.5M | 20.6M | 22M | 26M | 6.2M | 3.6M | 3.6M | |
0.0 | 0.0 | 0.0 | 768K | 0.0 | 0.0 | 75K | |
1.2M | 1.3M | 1.3M | 423K | 125K | 75K | 0.0 | |
19.7M | 21.9M | 23.3M | 27.2M | 6.3M | 3.6M | 3.7M | |
169.4M | 182.5M | 255.1M | 223.9M | 160M | 22.1M | 37.1M | |
LIABILITIES | |||||||
CURRENT LIABILITIES | |||||||
1.5M | 2.3M | 1.8M | 2.9M | 2.4M | 611K | 2.3M | |
1.5M | 2.3M | 1.8M | 2.9M | 2.4M | 611K | 2.3M | |
0.0 | 8.8M | 6.9M | 1.5M | 1.7M | 750K | 3.4M | |
3.2M | 0.0 | 0.0 | 0.0 | 0.0 | 15K | 0.0 | |
0.0 | 3.1M | 2.7M | 3M | 615K | 0.0 | 0.0 | |
13.6M | 618K | 935K | 3M | 2.7M | 1.3M | 405K | |
18.4M | 14.9M | 12.4M | 10.5M | 7.4M | 2.7M | 6.1M | |
NON-CURRENT LIABILITIES | |||||||
14.1M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 49K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 80K | 118.3M | |
14.1M | 15.6M | 16.9M | 17.9M | 360K | 80K | 118.3M | |
0.0 | 18.8M | 19.6M | 20.9M | 975K | 0.0 | 49K | |
32.5M | 30.5M | 29.2M | 28.4M | 7.7M | 2.7M | 124.5M | |
SHAREHOLDERS' EQUITY | |||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 128.1M | 118.2M | |
0.0 | 525.9M | 512.6M | 406.6M | 304.5M | 8.2M | 7.3M | |
-480.4M | -374.2M | -287.3M | -210.9M | -152.1M | -116.9M | -94.7M | |
-102K | 263K | 539K | -72K | 0.0 | 0.0 | 0.0 | |
617.4M | 0.0 | 1K | 0.0 | 0.0 | 0.0 | -118.2M | |
136.9M | 152M | 225.8M | 195.6M | 152.3M | 19.4M | -87.4M | |
136.9M | 152M | 225.8M | 195.6M | 152.3M | 19.4M | -87.4M | |
SUMMARY | |||||||
169.4M | 182.5M | 255.1M | 223.9M | 160M | 22.1M | 37.1M | |
84.7M | 119.4M | 185.1M | 68M | 0.0 | 0.0 | 75K | |
17.4M | 18.8M | 19.6M | 20.9M | 975K | 15K | 49K | |
-42.1M | -12.9M | -21.5M | -100.7M | -148.1M | -17.4M | -32.4M | |
62,119,873 | 62,119,873 | 62,119,873 | 62,119,873 | 62,119,873 | 62,119,873 | 62,119,873 |
SEC Filings
AURA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 11, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 11, 2026 | May 11, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 05, 2026 | May 04, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 04, 2026 | April 30, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 04, 2026 | April 29, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 20, 2026 | June 11, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 30, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 30, 2026 | March 30, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 13, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 13, 2025 | November 13, 2025 | 2025 |
Related Guides
Continue your AURA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.